Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Does prehabilitation modify muscle mass in patients with rectal cancer undergoing neoadjuvant therapy? A subanalysis from the REx randomised controlled trial.

Techniques in coloproctology·2020
Same author

Lifestyle in patients at increased risk of colorectal cancer.

Journal of human nutrition and dietetics : the official journal of the British Dietetic Association·2019
Same author

Overview of colorectal cancer screening.

Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland·2019
Same author

Prehabilitation is feasible in patients with rectal cancer undergoing neoadjuvant chemoradiotherapy and may minimize physical deterioration: results from the REx trial.

Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland·2019
Same author

Commentary: Reply to 'Accrediting colonoscopy services and colonoscopists for screening makes a difference'.

Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland·2018
Same author

The colorectal surgeon's personality may influence the rectal anastomotic decision.

Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland·2018
Same journal

Neoadjuvant tyrosine kinase inhibitor therapy for locally advanced, well-differentiated thyroid cancer.

The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland·2026
Same journal

Post-Endovascular Aneurysm Repair surveillance in the United Kingdom: A survey of current clinical practice.

The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland·2026
Same journal

Compatibility of family life with an academic career in plastic surgery: A European comparison.

The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland·2026
Same journal

Barriers to operative exposure in foundation training.

The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland·2026
Same journal

Mesenteric preservation vs extended mesenteric excision in Crohn's disease: A systematic review and meta-analysis.

The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland·2026
Same journal

The effect of a national healthcare cyberattack on the Irish hip fracture standards.

The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland·2026
See all related articles

Related Experiment Video

Updated: Jul 2, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

p53 as a therapeutic target.

O D Staples1, R J C Steele, S Lain

  • 1Department of Surgery and Molecular Oncology, Ninewells Hospital and Medical School University of Dundee.

The Surgeon : Journal of the Royal Colleges of Surgeons of Edinburgh and Ireland
|August 14, 2008
PubMed
Summary
This summary is machine-generated.

Researchers are developing new cancer therapies targeting the p53 tumor suppressor. Small molecules aim to restore p53 function in cancer cells, offering potential therapeutic benefits and reduced side effects.

More Related Videos

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence
04:56

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence

Published on: December 30, 2025

Purification of Ubiquitinated p53 Proteins from Mammalian Cells
10:55

Purification of Ubiquitinated p53 Proteins from Mammalian Cells

Published on: March 21, 2022

Related Experiment Videos

Last Updated: Jul 2, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence
04:56

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence

Published on: December 30, 2025

Purification of Ubiquitinated p53 Proteins from Mammalian Cells
10:55

Purification of Ubiquitinated p53 Proteins from Mammalian Cells

Published on: March 21, 2022

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • The p53 protein is a critical tumor suppressor, frequently inactivated in various cancers through mutation or negative regulation.
  • Restoring functional p53 in tumors has demonstrated therapeutic potential, revitalizing interest in p53 as a drug target.

Purpose of the Study:

  • To identify and develop small molecules that can counteract the loss of p53 function in cancer.
  • To explore compounds that either reduce negative regulation of wild-type p53 or reactivate mutant p53.

Main Methods:

  • Investigating small molecules for their ability to restore p53 tumor suppressor activity.
  • Evaluating compounds for their potential to inhibit negative regulators of p53.
  • Screening for small molecules capable of reactivating mutated p53 proteins.

Main Results:

  • Several small molecules have been identified that show promise in addressing both non-mutated and mutated p53 scenarios.
  • Some identified compounds may also mitigate side effects associated with conventional cancer treatments.

Conclusions:

  • Emerging strategies focus on small molecules to harness the tumor-suppressing capabilities of p53.
  • While promising, these therapeutic approaches are in early stages and require further validation.